Neoadjuvant immunotherapy for patients with resectable melanoma

View Full Paper

Ask AI

Bookmark

Neoadjuvant immunotherapy improved event-free survival, with a 12-month rate of 72%.
Among 118 patients analyzed, 42% achieved major pathological response after treatment.
This retrospective study assessed patients from three medical centers in Sweden between 2022 and 2024.
Real-world data support neoadjuvant immunotherapy's effectiveness for resectable stage III/IV melanoma.

Discussion

No takes yet. Share an insight, caveat, or question.

Retrospective analysis shows improved event-free survival in resectable melanoma with neoadjuvant therapy, highlighting its real-world efficacy.

Nelson et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Retrospective analysis shows improved event-free survival in resectable melanoma with neoadjuvant therapy, highlighting its real-world efficacy.